1. Academic Validation
  2. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review

Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review

  • Int J Mol Sci. 2021 Jan 8;22(2):561. doi: 10.3390/ijms22020561.
Valeria Di Battista 1 Maria Teresa Bochicchio 2 Giulio Giordano 3 Mariasanta Napolitano 4 Alessandro Lucchesi 1
Affiliations

Affiliations

  • 1 Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • 2 Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • 3 Division of Internal Medicine, Hematology Service, Regional Hospital "A. Cardarelli", 86100 Campobasso, Italy.
  • 4 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Haematology Unit, University Hospital "P. Giaccone", University of Palermo, 90127 Palermo, Italy.
Abstract

The last decade has been very important for the quantity of preclinical information obtained regarding chronic myeloproliferative neoplasms (MPNs) and the following will be dedicated to the translational implications of the new biological acquisitions. The overcoming of the mechanistic model of clonal evolution and the entry of chronic inflammation and dysimmunity into the new model are the elements on which to base a part of future therapeutic strategies. The innate immune system plays a major role in this context. Protagonists of the initiation and regulation of many pathological aspects, from cytokine storms to fibrosis, the NLRP3 and AIM2 inflammasomes guide and condition the natural history of the disease. For this reason, MPNs share many biological and clinical aspects with non-neoplastic diseases, such as autoimmune disorders. Finally, cardiovascular risk and disturbances in iron metabolism and myelopoiesis are also closely linked to the role of inflammasomes. Although targeted therapies are already being tested, an increase in knowledge on the subject is desirable and potentially translates into better care for patients with MPNs.

Keywords

AIM2; NLRP3; chronic inflammation; inflammasome; myeloproliferative neoplasms.

Figures
Products